Loading organizations...
§ Private Profile · Chengdu, Sichuan, China
Biopharmaceutical company developing targeted therapeutics for cancer and metabolic diseases using PROTAC and deuteration.
Hinova Pharma is a clinical-stage biopharmaceutical company based in Chengdu, Sichuan Province, China, focused on discovering and developing innovative drugs for cancer treatment and metabolic diseases using PROTAC and deuteration technology. The company, which employs 174 individuals, reported $9.6 million in revenue and has advanced its lead candidate, HC-1119, into phase III trials for castration-resistant prostate cancer. Prior to its April 2022 IPO on the Shanghai Stock Exchange, Hinova raised approximately $219 million across funding rounds, including a $147 million Series C in 2020. Notable investors include Shenzhen Investment Holdings, Hangzhou Tigermed, and Sinopharm Group, while its management team comprises individuals with experience from companies such as Abbott, Bayer, and Merck. Hinova Pharma was founded in 2013 by Dr. Yuanwei Chen.
Hinova Pharma has raised $147.6M across 1 funding round.
Hinova Pharma has raised $147.6M in total across 1 funding round.
Hinova Pharma has raised $147.6M in total across 1 funding round.
Hinova Pharma's investors include DNV Capital, Huarong Rongde, Infinity Group, Tigermed.
Hinova Pharma has raised $147.6M across 1 funding round. Most recently, it raised $147.6M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 7, 2020 | $147.6M Series C | — | DNV Capital, Huarong Rongde, Infinity Group, Tigermed | Announced |